

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REVOCATION OF POWER OF ATTORNEY, NEW POWER OF
ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTERMUNE INC., the owner of the entire right, title and interest in the attached listing of U.S. patent applications (Schedule A), hereby revokes all Powers of Attorney previously given in such patent applications. INTERMUNE INC. is the Assignee of the entire right and interest in each of these U.S. patent applications, as evidenced by the documentary evidence of the chain of title from the original owner to the Assignee, recorded in the Assignment records of the office at the reel/frame numbers indicated on Schedule A.

INTERMUNE INC. hereby appoints the attorneys and/or agents associated with customer number 89229 to prosecute these patent applications and transact all business in the U.S. Patent and Trademark Office.

Please recognize and change the correspondence address for the patent applications listed in Schedule A to the address associated with customer number 89229:

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300

INTERMUNE INC.


Name: John Bendrick

Title: Vice President, Intellectual Property, InterMune, Inc.

Date: March 2, 2010

Schedule A

MGB Reference	Application Number	Filing or 371 (c) Date	US Patent Applications	
			Title	Reel Frame
30481/30042	60/327,743	10/5/2001	Methods of treating liver fibrosis and hepatitis C virus infection	013214/0400
30481/30041	60/460,194	4/4/2003	Compositions and methods for treating viral infections	014749/0016
30481/30038	60/471,404	5/16/2003	Hybrid chemokine receptor ligands and methods of use thereof	014480/0790
30481/30046	60/471,841	5/16/2003	Combination IFN therapy	015175/0822
30481/30046A	60/485,474	7/8/2003	Combination IFN therapy for proliferative disorders	015175/0822
30481/30046B	60/511,415	10/14/2003	Interferon-gamma and TNF-alpha antagonist combination therapy for the treatment of fibrotic diseases	015451/0312
30481/30046C	60/511,280	10/14/2003	Combination therapy for the treatment of fibrotic diseases	014488/0659
30481/30046D	60/511,259	10/14/2003	Combination therapy for the treatment of fibrotic diseases	015531/0013
30481/30046E	60/514,173	10/24/2003	Combination therapy for treating proliferative disorders	014295/0659
30481/30047	60/511,169	10/14/2003	Combination therapy for the treatment of viral diseases	014282/0107
30481/30046F	60/561,940	4/13/2004	Combination therapy for the treatment of fibrotic diseases	014986/0522
30481/30048	60/579,625	6/14/2004	Interferon compositions and methods of use thereof	015241/0447
30481/30042A	10/490,457	8/16/2004	Methods of treating liver fibrosis and hepatitis C virus infection	015818/0726
30481/30040	60/660,074	3/8/2005	Use of alpha-glucosidase inhibitors to treat alphavirus infections	016089/0180
30481/30050	60/668,631	4/5/2005	Method of treating alphavirus infection	017138/0709
30481/30039	60/682,544	5/18/2005	Non-natural chemokine receptor ligands and methods of use thereof	018174/0953
30481/30048A	11/153,864	6/14/2005	Interferon compositions and methods of use thereof	016804/0339
30481/30040P	60/707,891	8/12/2005	Use of alpha-glucosidase inhibitors to treat alphavirus infections	017593/0867
30481/30043B	10/545,631	8/12/2005	Interferon drug therapy for the treatment of viral diseases and liver fibrosis	016997/0081
30481/30044A	10/552,020	10/3/2005	Compositions and methods for treating viral infections	016799/0876
30481/30046G	10/555,390	11/2/2005	Combination therapy for proliferative disorders	014986/0522
30481/30049A	11/356,634	2/17/2006	Biomarkers for predicting liver fibrosis treatment efficacy	017645/0626

